Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence
Authors' conclusion
These results show that treatment regimens including semaglutide 1.0 mg weekly lead to superior weight loss compared with liraglutide 3.0 mg daily for treating post-MBS weight recurrence, regardless of procedure type or the magnitude of weight recurrence.
Study context
- Population
- Adults with post-MBS weight recurrence, academic center, 2015–2021; mean age 55.2 years, mean BMI 40.4 kg/m², 89.9% female; 50% SG, 29% RYGB, 21% adjustable gastric banding
- Participants
- 207 adults
- Exposure
- Semaglutide 1.0 mg weekly vs liraglutide 3.0 mg daily
- Semaglutiden = 115
- Liraglutiden = 92reference
- Outcome
- Percentage body weight change
- Follow-up
- 12 months
Methodological detailssingle academic centre
- Single academic centre
Main finding
As reported in the abstract
Least-squares mean weight change
Semaglutide
−12.92
least-squares mean · %
Liraglutide
−8.77
least-squares mean · %
P < 0.001
Observational data: associations, not effects.
Further findings
| Outcome | aOR (95% CI) | |
|---|---|---|
| ≥10% weight loss · 12 months | 2.34 (1.28–4.29) | |
| ≥15% weight loss · 12 months | 2.55 (1.22–5.36) | |
| 0.20.5125Adjusted odds ratio (log scale) |
Subgroups (age, sex, MBS procedure)
- Weight-loss efficacy of semaglutide vs liraglutide did not differ by subgroups explored, including age, sex and MBS procedure
Original publication
Effectiveness of semaglutide versus liraglutide for treating post‐metabolic and bariatric surgery weight recurrence. Obesity (Silver Spring). Published 30 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →